Cited by 1,070Herpesvirus Infections and TreatmentsCytomegalovirus and herpesvirus researchVirology and Viral Diseases

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Open access

Cunningham, Anthony L., Lal, Himal, Kovac, Martina, Chlibek, Roman, Hwang, Shinn-Jang, Díez-Domingo, Javier, Godeaux, Olivier, Levin, Myron J., McElhaney, Janet E., Puig-Barberà, Joan, Vanden Abeele, Carline, Vesikari, Timo, Watanabe, Daisuke, Zahaf, Toufik, Ahonen, Anitta, Athan, Eugene, Barba-Gomez, Jose F., Campora, Laura, de Looze, Ferdinandus, Downey, H. Jackson, Ghesquiere, Wayne, Gorfinkel, Iris, Korhonen, Tiina, Leung, Edward, McNeil, Shelly A., Oostvogels, Lidia, Rombo, Lars, Smetana, Jan, Weckx, Lily, Yeo, Wilfred, Heineman, Thomas C.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1603800

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS: This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1:1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS: In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P<0.001) and was similar in participants 70 to 79 years of age (90.0%) and participants 80 years of age or older (89.1%). In pooled analyses of data from participants 70 years of age or older in ZOE-50 and ZOE-70 (16,596 participants), vaccine efficacy against herpes zoster was 91.3% (95% CI, 86.8 to 94.5; P<0.001), and vaccine efficacy against postherpetic neuralgia was 88.8% (95% CI, 68.7 to 97.1; P<0.001). Solicited reports of injection-site and systemic reactions within 7 days after injection were more frequent among HZ/su recipients than among placebo recipients (79.0% vs. 29.5%). Serious adverse events, potential immune-mediated diseases, and deaths occurred with similar frequencies in the two study groups. CONCLUSIONS: In our trial, HZ/su was found to reduce the risks of herpes zoster and postherpetic neuralgia among adults 70 years of age or older. (Funded by GlaxoSmithKline Biologicals; ZOE-50 and ZOE-70 ClinicalTrials.gov numbers, NCT01165177 and NCT01165229 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603800

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutiérrez‐Robledo, L. M., O'Donnell, M. J., Sullivan, R. J., & Yusuf, S. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 2,473
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Self-citation
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Self-citation
Systematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 943
A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction
Yawn, B. P., Saddier, P., Wollan, P. C., Sauver, J. L. S., Kurland, M. J., & Sy, L. S. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1341 · Cited by 866
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Herpes Zoster
Cohen, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmcp1302674 · Cited by 737
Postherpetic Neuralgia
Johnson, R. W., & Rice, A. S. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1403062 · Cited by 575
The incidence of herpes zoster in a United States administrative database
Insinga, R. P., Itzler, R. F., Pellissier, J. M., Saddier, P., & Nikas, A. A. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0150.x · Cited by 490
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Mechelen, M. V. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 318

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 3

Harpaz R, 2008, MMWR Recomm Rep, 57, 1
Chen N, 2014, Cochrane Database Syst Rev, CD006866
2011, MMWR Morb Mortal Wkly Rep, 60, 1528

Sorted by citations

Items 901–1,000 of 1,000

Spatiotemporal Components of Adverse Reactions Against BNT162b2 mRNA SARS-CoV-2 Vaccine Reflect Different Immunological ProcessesPreprint
Ikeda, K., Nakada, T., Kageyama, T., Tanaka, S., Yoshida, N., Ishikawa, T., Goshima, Y., Taniguchi, T., Igari, H., Hanaoka, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3903937
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Reid (2021) · The Journal of Family Practice · doi:10.12788/jfp.0216
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
Mottl (2021) · The Journal of Family Practice · doi:10.12788/jfp.0225
Improving Shingles Vaccination Rates in Family Medicine
Luther (2021) · The Journal of Family Practice · doi:10.12788/jfp.0218
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient
Lillo (2021) · The Journal of Family Practice · doi:10.12788/jfp.0224
Diabetes und Impfen
Lignitz, S., & Zepp, F. (2021) · Diabetes aktuell · doi:10.1055/a-1645-9479
Varicella and Zoster (Shingles)
Gershon, A. A. (2021) · doi:10.33442/vt202141
Are patients >50 years old who received a shingles vaccine, at lower risk of developing postherpetic neuralgia compared with those who did not receive shingles vaccine?
Kadia, K., Shelesky, G., Mehta, A., Haugh, A. J., & Friedlander, M. P. (2021) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001495
Organizing Pneumonia Following Recombinant Zoster Vaccination: A Rare Adverse Reaction
Khawaja, I., & Al-Ourani, M. (2022) · Cureus · doi:10.7759/cureus.21181
Prophylaxe, Diagnose, Therapie der Post-Zoster-Neuralgie
Sator, S. (2021) · Schmerz Nachrichten · doi:10.1007/s44180-021-0026-7
Disorders of the Peripheral Nervous System
Vitrikas, K., & Hurst, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-54441-6_74
Vaccination chez l’adulte: vaccins contre le zona et vaccination en cas d’asplénie anatomique ou fonctionnelle
Munting, A., & Crisinel, P. A. (2021) · JMIG · doi:10.53738/revmed.2021.17.734.0744
Pain Prevention
Jaffery, S. S., Tran, C., Ackerman, R. S., Loo, N. H., & Nasir, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-39982-5_32
Herpes zoster
秀夫, 浅. (2021) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.58.48
Romatoid artritli bir hastada sakral ve inguinal bölge tutulumu gösteren herpes zoster
Cesur, S., Siyah, U. O., Arslan, K., & KINIKLI, S. (2020) · Anatolian Current Medical Journal · doi:10.38053/agtd.604286
Herpesviruses (excluding Epstein–Barr virus)
Sissons, J. G. P. (2020) · doi:10.1093/med/9780198746690.003.0077
Postherpetic Neuralgia
Vora, A. J., & Chan, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-54947-9.00109-7
Vaccines
Damer, K. M., Maffeo, C. M., Zeitlin, D., Jung, C. M., & Cumbay, M. G. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.06.032
Systemic lupus erythematosus and infections
Devlin, A., & Shmerling, R. H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814551-7.00047-7
Varicella-Zoster Virus (Herpesviridae)
Cohen, J. I. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21315-0
Zona
Gaillat, J. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/j.rmra.2020.08.006
Human Vaccines & Immunotherapeutics: News
(2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1253965
Viral Infections
Wassilew, S. W. (2018) · Springer eBooks · doi:10.1007/978-3-319-69422-1_7
Management of Varicella-Zoster Virus Infections (Herpesviridae)
Sauerbrei, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-814515-9.00086-2
CMV seropositivity in older adults changes the T cell repertoire, but does not prevent antibody or cellular responses to SARS-CoV-2 vaccinationPreprint
Breznik, J. A., Huynh, A., Zhang, A., Bilaver, L., Bhakta, H., Stacey, H. D., Ang, J. C., Bramson, J. L., Nazy, I., Miller, M. S., et al. (2022) · medRxiv · doi:10.1101/2022.05.27.22275673
Serious Infections
Hartman, L., Tiller, R., Wohl, D. A., & van Duin, D. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.024
Screening and Prevention
Robertson, M. L., & Colburn, J. L. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.004
Immune Responses to Vaccination
Rohner, G. B., & Pittet, L. F. (2022) · In clinical practice · doi:10.1007/978-3-031-04844-9_2
Vaccinations for the ObGyn’s toolbox
Duff (2021) · OBG Management · doi:10.12788/obgm.0132
Herpes zoster und die Post-Zoster-Neuralgie
Isenmann, S., & Schürmann, N. (2022) · Schmerzmedizin · doi:10.1007/s00940-022-4004-1
Vaccines for the Elderly
Chiu, D. C. S. (2022) · Quality of life in Asia · doi:10.1007/978-981-19-3061-4_7
The Mechanism, Impact, and Effectiveness of Herpes Zoster Vaccine: A Narrative Review
Almutawa, Y. M., Bhattarai, E., & Zhao, J.-J. (2022) · International Journal of Dermatology and Venereology · doi:10.1097/jd9.0000000000000256
Herpes zoster und die Post-Zoster-Neuralgie
Isenmann, S., & Schürmann, N. (2022) · CME · doi:10.1007/s11298-022-3035-1
Vaccines
Ambler, A. W., & Brooks, B. D. (2022) · Side effects of drugs annual · doi:10.1016/bs.seda.2022.10.003
Pharmacothérapie. Nouveaux médicaments et vaccins disponibles en 2022
Haefliger, D., & Livio, F. (2023) · JMIG · doi:10.53738/revmed.2023.19.809-10.66
Wichtige Impfempfehlungen für Diabetiker
Moeser, A., & Pletz, M. W. (2023) · CardioVasc · doi:10.1007/s15027-023-2981-1
Wichtige Impfempfehlungen für Diabetiker
Moeser, A., & Pletz, M. W. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4469-6
Vaccines and the Prevention of Dermatologic Diseases
Bessa, G. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-13505-7_62
Le zona – Partie 3 : la prévention du zona et des névralgies post-zostériennes
Lang, P.-O. (2023) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/j.npg.2023.04.006
Infectious Complications After A Liver Transplant
Director of Agrinio ICU, T., Michailidou, E. M., Katsanos, G., Antoniadis, N., & Argiriadou, E. (2023) · Journal of Acute Care & Trauma Surgery · doi:10.33425/2837-7036.1004
Herpes-zoster-Infektionen. Akutbehandlung, Schmerztherapie bei Post-Zoster-Neuralgie und Impfung
(2020) · Zeitschrift für Allgemeinmedizin · doi:10.1007/bf03653197
Infectious Complications After A Liver Transplant
Director of Agrinio ICU, T., Michailidou, E. M., Katsanos, G., Antoniadis, N., & Argiriadou, E. (2023) · Surgery Research Journal · doi:10.33425/2768-0428.1023
An analysis and visualization of postherpetic neuralgia research between 1985 and 2022 using scientometricsPreprint
Cao, X., Zhang, M., Zhang, C., Jiao, B., Zheng, H., & Zhang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-3182112/v1
REPRINTED WITH PERMISSION OF IASP PAIN 164 (2023) 741748: Adjuvanted recombinant zoster vaccine decreases herpeszoster-associated pain and the use of pain medicationacross 3 randomized, placebo-controlled trials
Kim, J. H., Johnson, R. W., Kovac, M., Cunningham, A. L., Amakrane, M., Sullivan, K. M., Dagnew, A. F., Curran, D., & Schuind, A. (2023) · Ból · doi:10.5604/01.3001.0053.7735
Self-citation
An Evaluation of the Epidemiology, Vaccine Effectiveness and Vaccine Safety of Herpes Zoster Vaccination
Mbinta, F. (2023) · doi:10.26686/wgtn.23903745
Varizellen, Herpes zoster
Salzberger, B. (2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23817-8.00034-3
The Safety and Effectiveness of mRNA-1273, ???162b2, BNT162b1, ChAdOx1-nCoV-19 Vaccines Against Covid-19
Spyropoulou, G., Agathi Spiropoulou, M. S., Vasileios Spyropoulos, M. S., Lykouras, D., Karkoulias, K., & Spiropoulos, K. V. (2021) · Archives of Pulmonology and Respiratory Medicine · doi:10.22259/2639-362x.0401005
Vaccini e diabete: un legame da rafforzare nell’anno del centenario dalla scoperta dell’insulina
Peruzzi, O., Pratesi, A., Silverii, G. A., Dicembrini, I., & Diabete”, A. N. D. G. I. S.-A.-S. “. E. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01359-7
Herpes Virus Infections in Kidney Transplant Patients (HINT) – a prospective observational cohort study
Hamm, S. R., Saini, S. K., Hald, A., Vaaben, A. V., Pedersen, N. W., Suarez‐Zdunek, M. A., Harboe, Z. B., Brüünsgaard, H., Johansen, I. S., Larsen, C. S., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08663-5
Tiza–Titre increase and enhanced immunity through an adjuvanted, recombinant herpes zoster subunit vaccine in patients with liver cirrhosis and post-liver transplantation: a study protocol for a prospective cohort study
Vollmer-Raschdorf, S., Rashidi‐Alavijeh, J., Voigt, S., Hengel, H., Borchardt, B., Huzly, D., Huessler, E., der Schmitten, J. I., Halenius, A., Willuweit, K., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-074461
Tailoring Vaccines for Older Individuals: Aging of the Immune System and the Impact on Vaccine Efficacy
Bashir, S., Wilson, M., Ashiru-Oredope, D. A. I., & Murdan, S. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-35811-1_9
Recomendaciones para la inmunización con vacuna recombinante para herpes zóster en pacientes con enfermedades reumáticas inflamatorias crónicas autoinmunes
Bonvehí, P., Citera, G., Cosentino, V. L., la Vega, M. C. D., Larroudé, M. S., Nacinovich, F., Schneeberger, E. E., Vázquez, H., Zamora, N. V., Sorrentino, L., et al. (2023) · Revista Argentina de Reumatología · doi:10.47196/rar.v34i3.773
Impfen im Alter: eine Übersicht
Kwetkat, A., Leischker, A. H., Endres, A., & Heppner, H. J. (2023) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-023-02265-1
Herpes zoster in older patients
磯貝, 善. (2023) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.60.359
Vacunación contra el herpes zóster en adultos mayores: una revisión crítica
Mirofsky, M. (2024) · REVISTA ARGENTINA DE MEDICINA · doi:10.61222/ram.v11i4.907
Herpes Zoster bei entzündlich-rheumatischen Erkrankungen
Dartsch, R. C., Al-Azem, N., & Hasseli, R. (2024) · Aktuelle Rheumatologie · doi:10.1055/a-2195-1417
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV): a multicenter, international, non-randomized clinical trial study protocolPreprint
Hentzien, M., Bonnet, F., Bernasconi, E., Biver, E., Braun, D. L., Munting, A., Leuzinger, K., Leleux, O., Musardo, S., Prendki, V., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3955771/v1
Herpes zoster infections: epidemiology, diagnostics, and prophylaxis in light of a growing clinical problem
Własiuk, P., & Giannopoulos, K. (2024) · Hematology in Clinical Practice · doi:10.5603/hicp.96862
Neurological Aspects of Delusional Infestation
Oaklander, A. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-47032-5_10
Herpes Zoster Ophthalmicus in Two Virally Suppressed HIV-Positive Patients: Early Initiation of Therapy Improves Visual Outcome
Anyaso, O., Ikpe, G., Udeaja, A. C., Otuka, O. A. I., & Popoola, I. O. (2024) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2024.6.3.2114
Soreness and “flaking off” in right maxillary mucosa after eating chicken-fried steak
Cheng, Y. L., & Lee, C.-M. (2024) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2024.05.009
Herpes Zoster bei entzündlich-rheumatischen Erkrankungen
Dartsch, R. C., Al-Azem, N., & Hasseli, R. (2024) · Aktuelle Dermatologie · doi:10.1055/a-2312-5481
Background of Patients Who Received Two Doses of Adjuvanted Herpes Zoster Vaccine at a Clinic and Comparative Evaluation of Local and Systemic Adverse Reactions
Ohbayashi, H. (2024) · Japanese Journal of Infection Prevention and Control · doi:10.4058/jsei.39.37
Comment on Limitations of “Assessing Herpes Zoster Vaccine Efficacy in Patients With Diabetes: A Community‐Based Cohort Study”
Cohen, R., Yun, H., & Williams, C. (2024) · Journal of Medical Virology · doi:10.1002/jmv.70047
Varicella‐Zoster Virus
Greninger, A. L., & Koelle, D. M. (2023) · ClinMicroNow · doi:10.1002/9781683674849.mcm0102
Varicella‐Zoster Virus
Greninger, A. L., & Koelle, D. M. (2023) · ClinMicroNow · doi:10.1002/9781683670438.mcm0102
Disseminated herpes zoster presenting as atypical Ramsay-Hunt syndrome with oral lesions: A case report
Maruyama, S., Ichimura, N., Wakayama, Y., Omori, M., Sakaguchi, K., Okabe, K., Maruyama, H., & Hibi, H. (2025) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2025.02.010
Effect of herpes zoster vaccine on patients after hematopoietic stem cell transplantation: a systematic review and meta-analysis
Jiao, X., Zhu, J., Ding, Y., Xiao, M., & Zhai, Z. (2025) · Virology Journal · doi:10.1186/s12985-025-02670-5
Non-Adjacent Bilateral Postherpetic Neuralgia in a Multiple Myeloma Patient: A Case Report
Zhang, H., He, J., Du, Z., Zhou, J., & Xia, J. (2025) · American Journal of Case Reports · doi:10.12659/ajcr.946562
Off-label use of recombinant adjuvanted Herpes Zoster vaccine in a 10-year-old high-risk patient affected by epidermolysis bullosa: A case report
Palmieri, C., Noviello, C., Moscara, L., Stefanizzi, P., Berti, I., Tafuri, S., & Arbo, A. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2494457
Impfen im Alter
Kwetkat, A., & Heppner, H. J. (2025) · Elsevier eBooks · doi:10.1016/b978-3-437-21194-2.00025-4
Antigen-specific Th17 T cells offset the age-related decline in durable T cell immunityPreprint
Sturmlechner, I., Jain, A. K., Jiang, J., Okuyama, H., Mu, Y., Own, M., Weyand, C. M., & Goronzy, J. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.05.658069
Herpes Zoster and Cardiovascular Health: Preventing Glycocalyx Damage-induced Vascular Failure
Yamaoka‐Tojo, M., & Tojo, T. (2025) · Vascular Failure · doi:10.30548/vascfail.9.1_1
Opportunistic Infections
Han, S., Martin, S. R., & Bryant, R. V. (2025) · Springer eBooks · doi:10.1007/978-3-031-87503-8_24
Vaccination for older people in post-COVID-19 era: challenges and strategies for improvement
Wong, C. W. (2025) · Asian Journal of Gerontology and Geriatrics · doi:10.12809/ajgg-2024-710-ra
AS01-adjuvanted vaccine alters baseline correlates of T cell response to varicella zoster virus in older adults
Chan, C., Ooi, J. S. G., Koh, C. W., Ong, E. Z., Tham, C. Y. L., Yee, J. X., Chew, V. S. Y., Cheung, Y. B., Ooi, E. E., Low, J. G. H., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127396
VACCIN SHINGRIX CONTRE LE ZONA CHEZ LE SUJET AGE : QUE FAUT-IL PENSER ?
SCIENTIFIQUE, C. (2025) · EXERCER · doi:10.56746/exercer.2025.215.318
Vaccination in adults at-increased risk of herpes zoster in Canada: insights from a multidisciplinary panel consensus
Ghesquière, W., Tessier, D., Brown, V., Guenther, L., Haaland, D. A., Igoe, J., MacDonald, K. S., & Whiskin, C. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2539884
Immunsuppression bei Krebs: Schutz vor Infektionen
Schwicht, C., von Bergwelt‐Baildon, M., & Spiekermann, K. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2414-8494
Impfungen in der Nephrologie
Girndt, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00867-x
Molecular ingredients of an immunogen for long-lasting IgG
Gupta, S. L., Meyer, A. R., Kay-Tsumagari, E., & Cheng, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639371
Perspectives on the History and Epidemiology of the Varicella Virus Vaccine and Future Challenges
Nagasawa, M. (2025) · Pathogens · doi:10.3390/pathogens14080813
Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China
Liu, L., Zhang, Q., Shu, Y., Wang, L., Shuai, Z., Chu, M., Zhang, Z., & Zhang, R. (2025) · PharmacoEconomics - Open · doi:10.1007/s41669-025-00604-z
Herpes zoster reactivation in a cohort of people living with HIV vaccinated with recombinant vaccine
Arsuffi, S., Rossi, L., Colombo, F. R., Inverardi, M., Mirovic, E., Laurenda, D., Izzo, I., Rapino, S., Castelli, D., Gaffurini, F., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127723
Mapping the landscape of herpes zoster vaccine research: A bibliometric analysis
Lu, R., Bao, S., Zhang, J., Yang, Y., Wang, Y., Zhou, Y., Zhou, P., & Yuan, X. (2025) · Medicine · doi:10.1097/md.0000000000044741
Predictive model of public health impact of herpes zoster vaccination and related costs for adults aged ≥50 years in Republic of Korea
Min, S., Kwon, S., Seo, J., Nam, J. H., Park, J.-H., Kwon, T., Kang, H., Ng, C., & Lee, E. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2554488
The immunogenicity of recombinant zoster vaccination in patients with secondary immunodeficiencies: a literature review
Kuipers, S. D., Knoester, M., Hazenberg, C. L. E., van Baarle, D., & van der Heiden, M. (2025) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2025.100231
Insights into tumor vaccines for elderly individuals in the context of immunosenescence
Li, C., Chen, Z., Zhu, C., Chen, M., Li, J., Zhong, L., & Hou, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1660874
Informing decisions in light of parameter uncertainty – an economic evaluation of the adjuvanted recombinant herpes zoster vaccine in Sweden
Nystrand, C., Widgren, K., Hao, S., Heintz, E., & Sparring, V. (2025) · The European Journal of Health Economics · doi:10.1007/s10198-025-01829-9
Identifying plausible ranges for differential vaccine efficacy across high- and low-income settings: A Systematic Review, Descriptive Meta-Analysis, and illustrative evidence analysis.
Katama, E. N., Gallagher, K. E., Shah, A. S. V., Nokes, D. J., & McAllister, D. (2025) · Wellcome Open Research · doi:10.12688/wellcomeopenres.24913.1
Sex and age-related differences in humoral and cellular responses to the recombinant zoster vaccine in people living with HIV
Díez, C., Pita-Martínez, C., Quero‐Delgado, M., Tórtola, A. G., Fanciulli, C., Marchan, A., Aldámiz‐Echevarría, T., Sepúlveda‐Crespo, D., Tejerina, F., Latorre, L. P., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118663
Herpes Zoster Vaccination and Influencing Factors of Vaccination Willingness among Older Adults in Chongqing
郑, 嘉. (2025) · Statistics and Applications · doi:10.12677/sa.2025.1410294
Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial
Kameda, H., Takeuchi, T., Yamaoka, K., Oribe, M., Kawano, M., Konishi, Y., Chonan, S., Ikeda, K., Camp, H. S., & Tanaka, Y. (2025) · RMD Open · doi:10.1136/rmdopen-2025-006213
Impact of vaccination on shingles-related hospitalisations in 70–79-year-olds in Scotland between 2000 and 2023: A retrospective cohort study
Kouzeli, A., Hasan, T., Smith, K., Metelmann, S., Gibbons, C., & Ghebrehewet, S. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127951
Herpes Zoster Vaccination
Gabutti, G., & Flamaing, J. (2025) · Springer eBooks · doi:10.1007/978-3-032-04020-6_12
Vaccination of older adults
Harbsmeier, A. N., Schultz, M., Ekenberg, C., Larsen, C. S., Usinger, L., & Harboe, Z. B. (2025) · Ugeskrift for Læger · doi:10.61409/v04250252
Herpes zoster vaccine awareness and determinants among chinese adults aged ≥ 60 years: a cross-sectional study
Dai, J., Wang, Y., Yuan, S., Chen, Y., Zhang, Z., Zhu, L. X., Liu, G., Zeng, Q., Qiu, Q., Luo, C., et al. (2025) · Expert Review of Vaccines · doi:10.1080/14760584.2025.2596677
Real-world utilization and potential clinical and economic value of recombinant zoster vaccine and select preventive services recommended for older adults in the United States
Gatwood, J. D., Gomez-Espinosa, E., Fusco, N., Stempniewicz, N., & Singer, D. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128015
Empfehlungen für die Impfung Erwachsener für Pneumologen
Ewig, S., Hinze, C. A., Vogelmaier, C., Stierl, M., & Rademacher, J. (2025) · Pneumologie · doi:10.1055/a-2732-6651
Additional file 1 of Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study
Werner, F., Zeschick, N., Kühlein, T., Steininger, P., Überla, K., Kaiser, I., Sebastião, M., Hueber, S., & Warkentin, L. (2023) · Figshare · doi:10.6084/m9.figshare.24165104

Authors: Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., Godeaux, O., Levin, M. J., McElhaney, J. E., Puig-Barberà, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., de Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., McNeil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., & Heineman, T. C.
Affiliations: The University of Sydney (AU)
Uppsala University (SE)
ORCID: Cunningham, Anthony L.
Lal, Himal
Hwang, Shinn-Jang
Godeaux, Olivier
Levin, Myron J.
McElhaney, Janet E.
Watanabe, Daisuke
Zahaf, Toufik
Athan, Eugene
de Looze, Ferdinandus
Gorfinkel, Iris
McNeil, Shelly A.
Oostvogels, Lidia
Rombo, Lars
Smetana, Jan
Weckx, Lily
Yeo, Wilfred
Heineman, Thomas C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-09-15
Volume: 375
Issue: 11
Pages: 1019-1032
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1603800
OpenAlex: W2519957152
Cited by: 1,070
References: 31
Citations by year: 2026: 96 · 2025: 124 · 2024: 107 · 2023: 97 · 2022: 91 · 2021: 120 · 2020: 94 · 2019: 117 · 2018: 138 · 2017: 75 · 2016: 11
FWCI: 106.61
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Online (University of Wollongong) (submittedVersion)
Figshare (submittedVersion, cc-by)
CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
Funders: Bristol-Myers Squibb
Pfizer
AstraZeneca
Sanofi
Novo Nordisk
Astellas Pharma
H. Lundbeck A/S
Sanofi Pasteur
Topics: Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
Keywords: herpes zoster, postherpetic neuralgia, vaccine efficacy, older adults, AS01B adjuvant, vaccine safety, herpes zoster incidence, vaccine adverse events, immunosenescence, immunogenicity
MeSH terms: Aged, Aged, 80 and over, Double-Blind Method, Female, Herpes Zoster, Humans, Male, Middle Aged, Risk, Vaccines, Subunit, Neuralgia, Postherpetic, Herpes Zoster Vaccine, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks